科研 - 新产品及分析技术开发


  • 我们不断开发新的遗传分析技术及其临床应用. Rainbow Genomics constantly develops new genetic analysis technologies and their clinical applications

  • 通过与我们合作的临床医学伙伴及其科学平台,我们开发了以下新的产品和遗传分析技术. By working with our clinical partners and their platforms, we developed the following new products and genetic analysis technologies


“小兒1000”检测研发

Healthy Pediatric Exome Screening Test Product Development

  • Rainbow “小儿1000”检测 - 是依据美国哈佛大学医学院和波士顿儿童医院实施的BabySeq儿科基因筛查计划为蓝本。我们除了引进了这种新的基因检测策略我们还与Fabric Genomics共同开发了大约200个额外的基因组。该基因组包括针对儿科疾病的最新基因注释(文献发表于2018)。我们的“小儿1000”检测现在已经包含了1700个,与1000多种儿科疾病相关的基因

  • 目前亚洲尚无此类基因筛查检测

  • For the Healthy Pediatric Exome Screening Test, which is based on the BabySeq project implemented at the Boston Children’s Hospital and Harvard Medical School, we co-developed an additional gene panel of approximately 200 genes with Fabric Genomics. The panel includes the latest genes annotated (2018) for childhood-onset disorders. Our total interpretation menu now includes 1700 genes associated with over 1000 childhood-onset genetic disorders.


用于全外显子组的心脏基因分析研发

Cardio Panel for Focused Heart Disease Analysis Coupled with UCLA Whole Exome Clinical Interpretation

  • 与洛杉矶加州大学临床基因组学中心的团队合作,Rainbow共同开发了一个有100多个基因的基因组,针对单基因心血管疾病和肌肉萎缩症

  • 通过订购"成人儿科全外显子组检测“,医生可以另外订购这个心脏基因组分析(不额外收费)。这个有助于UCLA的医学团队能够解释患者症状的同时,也关注一系列心血管疾病基因变异

  • By working with the team at UCLA’s Clinical Genomic Center, Rainbow co-developed a cardio panel with over 100 genes that target monogenic cardiovascular diseases and muscular dystrophy disorders.

  • This panel is now available for order with the UCLA adult and pediatric whole exome sequencing test, enabling their medical team to focus on a range of cardiovascular disorders while interpreting patient’s other symptoms.


用于全外显子组的癌症基因分析研发

并加入了常见癌症的风险评估以降低患病风险

Cancer Gene Panel for Comprehensive Cancer Screening Coupled with Baylor’s Exome Clinical Interpretation

Integrated Common Cancer Risk Assessment to Motivate Improved Liefstyle

  • 与Baylor Genetics的临床医学团队合作,Rainbow共同开发了100多种基因,用于筛选大多数已知的遗传性癌症的基因变异。这是对没有症状或家族史的个人的最全面的癌症筛查检测.

  • 我们也采用SNP标记对7种常见癌症进行风险评估.

  • 癌症60种檢測 - 我们率先使用遗传性癌症风险(与非基因变异携带者相比,风险高5-20倍)和普通癌症风险(与非基因变异携带者相比,风险高1.3-3倍)。结合的报告可以激励患者改善个人生活方式。改善生活方式和饮食习惯可以帮助降低整体癌症风险.

  • 目前亚洲尚无此类携带”临床应用性”的癌症基因筛查检测

  • Working with Baylor Genetics’ clinical team, Rainbow co-developed over 100 genes for screening of most known hereditary cancer gene variants. This is the most comprehensive cancer screening test available to individuals without symptoms or family history.

  • Rainbow also adopts the use of SNP (Single Nucleotide Polymorphism) markers for risk assessment of seven common cancers. We are among the first to provide both hereditary cancer risk (5-20 times higher risk compared to non-carriers) and common cancer risk (1.3-3 times higher risk compared to non-carriers) to motivate individuals to improve their life style/follow screening guidelines.